DJIA 17,191.51 -88.23 -0.51%
NASDAQ 4,519.07 -60.72 -1.33%
S&P 500 1,993.77 -16.63 -0.83%
market minute promo

Dendreon Corp (NASDAQ: DNDN)

1.56 0.06 (3.67%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

DNDN $1.56 3.67%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.53
Previous Close $1.50
Daily Range $1.46 - $1.57
52-Week Range $1.24 - $3.52
Market Cap $249.3M
P/E Ratio -1.10
Dividend (Yield) $0.00 (0.0%)
Volume 2,822,038
Average Daily Volume 3,083,593
Current FY EPS -$0.73





Dendreon Corp (DNDN) Description

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website:

News & Commentary Rss Feed

Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014

Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape

Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious

Medivation Eyes Blockbuster As Cancer Drug Gets An OK

Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's Blockbuster Prostate Ca

Medivation and Astellas get expanded FDA approval for Xtandi with a label that looks better than Johnson & Johnson's Zytiga.

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

MannKind Corp. And The Folly Of Cult Biotech Stocks

Aug. 18 Premarket Briefing: 10 Things You Should Know

Ebola Vaccine and Inhaled Insulin Incoming

Biotech partnerships, an IPO that wasn't, and how big data is fighting Ebola.

A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

See More DNDN News...

DNDN's Top Competitors

DNDN $1.56 (3.67%)
Current stock: DNDN
AMGN $141.36 (-1.84%)
Current stock: AMGN
GILD $104.76 (-1.13%)
Current stock: GILD
BIIB $326.32 (-0.89%)
Current stock: BIIB